A Remotely Delivered Episodic Future Thinking Intervention to Improve Management of Type 2 Diabetes

Phase 1

Completed

• Conditions: Type 2 Diabetes
• Interventions: Behavioral: Episodic future thinking; Behavioral: Control Thinking

• Registration Number: NCT03732209
• Lead Sponsor: Virginia Polytechnic Institute and State University

Brief Summary

The goals of this project are to assess the efficacy of remotely delivered episodic future thinking for reducing delay discounting and improving management of type 2 diabetes, including glycemic control, weight loss, medication adherence, dietary intake, physical activity, and blood pressure. This will be accomplished by randomly assigning participants (N = 64) to episodic future thinking or control thinking groups, while tracking outcome measures before, during, and after the 4-month intervention, as well at a 6-month follow-up visit. Participants in both groups will also receive access to an information-based weight loss intervention.

Detailed Description

Participants (N = 64) will be randomly assigned to either an episodic future thinking group or control thinking groups. Participants will generate episodic future events or control information, as well as related text-based cues, and will be prompted via smartphone or web application to engage in episodic future or control thinking frequently in their natural environment (e.g., at home or work, before meal times, and in high-risk situations) for a 4-month period. Participants in both groups will be provided with one-on-one, phone-based case management and provided with instructional materials and behavioral tools for weight loss and diabetes management. Instructional materials will include: 1) a modified version of the Traffic Light Diet, which utilizes red, yellow, and green labels for food to guide participants toward the goal of consuming low energy dense, low glycemic, high nutrient dense foods; 2) the Traffic Light Activity Program, which also utilizes red, yellow, and green labels for different levels of caloric expenditure, and 3) tools for self-monitoring of weight, diet, and/or physical activity.

Participants will complete four laboratory-based assessment sessions in which the investigators assess body weight, height, waist and hip circumference, glycemic control (HbA1C), adherence to oral glucose-lowering medication, delay discounting, reinforcing efficacy of food, and blood pressure. These assessments will be completed before the intervention (Week 0), during the intervention (8 weeks), and immediately after the intervention (Week 16), as well after a 2-month post-intervention follow-up (Week 24). The latter three assessments sessions will also include questions to measure participants' perceived effectiveness and ease of use of the intervention. Participants will also complete several remote assessments, including dietary intake and physical activity (during Weeks 0, 8, and 16; via accelerometer), as well as delay discounting and reinforcing efficacy of food (during Weeks 3, 8, and 16).

Study Timeline

• Study First Submitted: 2018-11-04
• Study First Submitted QC: 2018-11-04
• Study First Posted: 2018-11-06
• Study Start: 2019-03-01
• Primary Completion: 2021-08-31
• Study Completion: 2021-08-31
• Results First Submitted: 2022-11-18
• Status Verified: 2024-10
• Results First Submitted QC: 2024-10-31
• Last Update Submitted: 2024-10-31
• Results First Posted: 2024-11-01
• Last Update Posted: 2024-11-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 59

Inclusion Criteria

• Overweight or obese (BMI of 25 or greater)
• Poorly controlled type 2 diabetes (HbA1C of 8% or greater)
• Prescribed or recommended oral glucose-lowering medication

Read More

Exclusion Criteria

• Current insulin therapy for type 2 diabetes
• History of gestational diabetes
• Pregnant or lactating
• Not ambulatory
• Intellectual impairment
• Unmanaged medical or psychiatric disorder
• Abnormal glucose related to medications (e.g, glucocorticoids)

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Episodic future thinking	Episodic future thinking	Participants will generate positive future events and related text cues that will be accessed via an electronic app to engage in episodic future thinking.
Control thinking	Control Thinking	Participants will generate non-future-oriented information and related text cues that will be accessed via an electronic app to engage in control thinking..

Primary Outcome Measures

Name	Time	Method
Change in Glycosylated Hemoglobin	Baseline, 8 weeks, 16 weeks, and 24 weeks	Glycemic control will be assessed by change in glycosylated hemoglobin (hemoglobin A1C, or HbA1c), a standardized diagnostic measure for type 2 diabetes.; Negative change scores indicate a reduction in percentage of glycosylated hemoglobin (improved glycemic control); positive scores indicate an increase in percentage of glycosylated hemoglobin (worsened glycemic control)
Change in kg/m^2 (Body Mass Index)	Baseline, 8 weeks, 16 weeks, and 24 weeks	Change in kg/m\^2 (body mass index) will be measures using a digital scale; Negative scores indicate reductions in kg/m\^2; positive scores indicate increases in BMI.
Change in Delay Discounting Area Under the Curve (Normalized)	Baseline, 8 weeks, 16 weeks, and 24 weeks	Delay discounting will be assessed using a computerized task that assess participants' indifference points, or the objective amount of a smaller, immediate reward that is subjectively equivalent to a delayed, larger reward ($100), across a range of delays (1 month, 3 months, 6 months, 1 year, 3 years, 5 years, and 12 years). Indifference points will be expressed as a proportion of the larger reward (0 to 1). This delay discounting curve (indifference points as a function of delay) will be summarized using area under the curve (AUC), calculated using subjective value of the delayed reward (0 to 1) as the y-axis unit and delay as the x-axis unit. Individual delays are converted to ordinal units (1-7) prior to analysis. AUC is expressed as a proportion of the maximum possible AUC. This normalized measure of AUC varies from 0 (maximum discounting) to 1 (minimum discounting).; Positive scores indicate reductions in delay discounting (i.e., increases in AUC across time); negative sco

Secondary Outcome Measures

Name	Time	Method
Perceived Treatment Effectiveness	8 weeks, 16 weeks, and 24 weeks	Perceived treatment effectiveness for the EFT and control conditions will be measured using a 5-point scale, ranging from 1 (not at all) to 5 (extremely).; Higher scores reflect greater perceived effectiveness.

Trial Locations

Locations (1)

Fralin Biomedical Research Institute; 🇺🇸 Roanoke, Virginia, United States